Diagnostic screening for prostate cancer includes digital rectal examination and serum PSA. However several studies have shown that screening using serum PSA and digital rectal examination, did not significantly decrease prostate cancer-specific mortality. The advent of MR in prostate imaging has changes this and the ESUR published prostate MR guidelines in 2012 and also the PIRADS reporting system. Our study aims to assess the ability of mp-MRI to serve as a screening tool for detection of prostate cancer, to evaluate the ESUR PIRADS scoring system for prostate cancer detection using multiparametric MRI, to find a threshold PI-RADS sum (PIRADS-S) score for detection of prostate cancer and to evaluate the usefulness of mp-MRI in patients with serum PSA of ≤10 ng/mL in diagnosing prostate cancer. From the 54 subjects included, a total of 274 sectors were taken for analysis. All patients underwent mpMRI which included T2,DWI and dynamic contrast enhanced imaging. Using ESUR guidelines individual PI-RADS scores (T2WI, DWI and DCEI) were assigned for all sectors of prostate, following which PI-RADS sum (PIRADS-S = T2WI+DWI+DCEI) score was calculated for each sector. TRUS guided modified sextant biopsy of prostate was done for all patients and correlated with imaging. Statistical analysis was done using independent samples t test and ROC analysis. Sensitivity, specificity, predictive values and likelihood ratios were calculated at various cut-off levels. Optimal cut-off point was calculated by using Youden's statistics. From this study, ESUR PIRADS scoring system showed good diagnostic performance for detection of prostate cancer by using mpMRI and DWI showed the best diagnostic performance. The ROC analysis of PIRADS-S score revealed area AUC of 0.933 with p value of < 0.001. The reported AUC of PIRADS-S score in detecting carcinoma prostate was 0.768 to 0.93. The diagnostic performance of mpMRI was analysed in a group of subjects with serum PSA of ≤ 10 ng/mL. mpMRI showed high negative predictive value which indicates the ability of the test to predict the absence of disease with high confidence, thereby helping to avoid a prostate biopsy.
Introduction
Prostate cancer is the second most frequently diagnosed cancer of men and fourth most common cancer overall. In 2012, 1.1 million men were diagnosed with prostate cancer worldwide, accounting for 15% of cancers diagnosed in men. Incidence rates vary more than 25-fold worldwide, the highest rates being in Australia/New Zealand and North America, the lowest in Eastern Asia and South-Central Asia, and intermediate in Central and Eastern Europe. Almost 70% of new cases are being detected in developed countries, because of the widespread practice of serum prostate specific antigen (S.PSA) testing and subsequent biopsy. Incidence rates are low in South-Central Asian population with estimated incidence rates of 4.5. In India 19,000 men were diagnosed with prostate cancer in 2012 with a 5 year prevalence of 64,000. (1) The main aim of screening methods is to reduce disease specific and overall mortality and morbidity. Screening for prostate cancer is to be performed in the absence of any symptoms or indications of disease, which include digital rectal examination (DRE) and serum prostate-specific antigen (PSA) assay. Digital rectal examination (DRE) as a screening tool has limited utility due to poor reliability, low sensitivity and a predominant assessment of the peripheral zone. This is especially so for small tumours that have not reached the prostatic capsule. (2) The reported sensitivity and specificity of DRE in prostate cancer detection is 37% and 91% with even lower sensitivity with normal serum PSA levels (0 -4ng/mL). (3) Serum PSA estimation: PSA is an enzyme secreted by the epithelial cells of prostate, which is the main source of serum PSA. The normal range of serum PSA is taken as 0-4 ng/mL. Serum PSA levels are elevated in patients with a range of prostatic diseases including carcinoma prostate, benign hypertrophy, prostatitis and prostatic infarction. (4) After introduction of this test in clinical practice the incidence of prostate cancer increased significantly with a concomitant lowering of stage at diagnosis. However the specificity is low especially between the levels of 4 -10 ng/mL. Hence 60-75% of men with PSA levels greater than 4 ng/mL undergo unnecessary biopsy. (5) Similarly using this cut-off value (4 ng/mL) for men of all ages, results in exclusion of a high number of patients with clinically significant early-stage disease, as, approximately 20% to 50% of clinically significant organ-confined carcinoma prostate occurs in men with serum total PSA of less than 4 ng/mL. (6) Because of the low specificity and relatively low sensitivity of serum PSA estimation, various methods have been proposed to increase the specificity of PSA, including age-specific PSA reference ranges, PSA density (PSAD) and percent free PSA (% f PSA). Percent free PSA increases the specificity with maintained high sensitivity compared to age specific PSA ranges and PSA density. (7) Combined meta-analysis of five RCTs showed that prostate cancer screening using serum PSA and digital rectal examination, did not significantly decrease prostate cancer-specific mortality. So, men who have a life expectancy of less than 10 to 15 years are unlikely to benefit from screening. (8) The advent of MR in prostate imaging has changes this. Until recently there was no definite accepted guideline for prostate cancer detection and staging on MRI. In 2011 Dickinson L et al, presented recommendations on a standardized method for the conduct, interpretation, and reporting of prostate mp-MRI for prostate cancer detection and localization. (9) Following this the European Society of Urogenital Radiology (ESUR) proposed the ESUR prostate MR guidelines in 2012. This report provides the guidelines for magnetic resonance imaging (MRI) in prostate cancer (minimal and optimal imaging acquisition protocols) and a structured reporting system which was described as PIRADS (Prostate Imaging Reporting And Data System) scoring system. (10) This study was designed with the following objectives in mind. Primary Objective: To assess the ability of mp-MRI to serve as a screening tool for detection of prostate cancer 
Materials and Methods
The study was designed as a prospective single institutional study and was approved by institutional review board. Patients with either increased serum PSA or abnormal DRE, who were referred for mpMRI and TRUS guided prostate biopsy were included as study subjects.
Between January 2013 to September 2014, 54 consecutive patients were registered as study subjects. Patients with previous history of other pelvic malignancy, contraindication for MRI or TRUS biopsy were excluded from the study. All patients underwent mpMRI which includes T2 weighted imaging, diffusion weighted imaging and dynamic contrast enhanced imaging at 1.5T. Endorectal coil (ERC) was used for optimal signal reception and bowel preparation was done with cleansing enema. High resolution axial fast spin echo T2 weighted images were taken initially perpendicular to the plane of prostatic urethra, followed by sagittal and coronal high resolution T2 weighted images. Diffusion weighted images at two b values (0 and 800) were obtained in the same plane as axial T2W sequence and ADC maps were generated using standard post processing software. DCE MRI was obtained by a 3D T1 weighted GRE sequence in the same plane as axial T2W sequence with a temporal resolution of 15 sec for 5 mins, following an intravenous bolus injection of 0.1mmol/kg body weight of gadolinium based contrast. MRI interpretation was done on GE Centricity PACS work station by a single qualified radiologist. The prostate gland was divided into 8 segments, 6 from peripheral zone (basal, mid and apical third on both sides) and 2 from central gland (right and left). On mid sagittal high resolution T2W image the superoinferior dimension of the prostate was measured, which was then divided into 3 equal portions on both sides of the peripheral zone. Central gland was divided into right and left on axial high resolution T2W images. On high resolution T2W images each sector was examined for focal lesion or signal intensity changes, followed by DWI-ADC and DCEI analysis. Using ESUR guidelines ( week to 2 month period, using an ultrasound scanner with a 6 MHz transrectal probe and biopsy adapter. Similar to MRI interpretation, on mid sagittal view, supero-inferior dimension of prostate was measured, and was divided into 3 equal portions on both sides of peripheral zone. Central zone was divided into two. Biopsy cores (one each) were obtained from the sextants of the peripheral zone. All cores were obtained using an 18-gauge biopsy gun. All cores were labelled according to their sextant topographic location as the base, mid gland and apex, from each side of the gland. Histopathology of all sextants were recorded with Gleason score. Each sector scored by PIRADS system was then compared with histopathology of the corresponding core. Statistical analysis: Independent samples t test was applied in mean of serum PSA between adenocarcinoma positive and negative groups. Diagnostic accuracy of individual (T2W, DWI and DCEI) PIRADS score and PIRADS-S score were assessed by using receiver operating characteristic (ROC) analysis. The area under the ROC curve (AUC) is a measure of how well a parameter can distinguish between two diagnostic groups. Sensitivity, specificity, predictive values and likelihood ratios were calculated at various cut-off levels. Optimal cut-off point was calculated by using Youden's statistics. A twotailed p value of 0.001 or less was considered statistically significant.
Results
Fifty four subjects were included in the study with median age of 56 years and range of 52 to 86 years ( Table 2 , Fig XI) . Twenty seven out of fifty four subjects were positive for carcinoma prostate ( Fig XII) . Serum PSA ranged from 1 to 120 ng/mL in carcinoma prostate positive group and 3 to 69 ng/mL in negative group ( Fig XIII) . Eighteen out of fifty four subjects had serum PSA of ≤10 ng/mL, with 9 subjects showed positive for malignancy. Number of available sectors with corresponding biopsy cores in that group were 86 (Positive -20, Negative -66). Gleason score 3+3 was the most common score encountered in this group with 14 out of 20 positive cores (70%) ( Fig  XXIX) . ROC curve analysis of PIRADS-S score showed area under the curve (AUC) of 0.93 with p value of < 0.001. Youden selected threshold for PIRADS-S score for detection of prostate cancer in patients with S.PSA ≤10 ng/mL was 8 with the sensitivity, specificity, positive and negative predictive values of 85%, 87.88%, 68% and 95.1% respectively (Table 8 ). .9% with the cut-off of 10, which is comparable with our study. In our study, Youden selected threshold PIRADS-S score was 9 (≥ 9) with Youden index (J) of 0.744. By lowering the PIRADS-S cut-off score from 10 to 9, we can achieve relatively good sensitivity (68.4% to 78.95%) with preserved specificity (98.5% to 95.45%). The diagnostic performance of mpMRI was analysed in a group of subjects with serum PSA of ≤ 10 ng/mL. ROC analysis of PIRADS-S score showed area under the curve (AUC) of 0.93 with p value of < 0.001 for the detection of prostate cancer. 13 sectors were scored ≥ 10 and all were positive for malignancy with 100% positive predictive value. Youden selected threshold cutoff was 8 (≥ 8) with sensitivity, specificity, positive predictive and negative predictive value of 85%, 87.88%, 68% and 95.1% respectively. mpMRI showed high negative predictive value with PIRADS-S score cut-off 8, which indicates the ability of the test to predict the absence of disease with high confidence. This factor can be used to limit unnecessary biopsy of prostate. From the above observations, it is safe to say that mp-MRI is able to predict the presence or absence of disease with accuracy levels much greater than that of serum PSA estimation or DRE, which form the mainstay of screening in current clinical practice. The projected high cost of MR for application as a screening tool often downplays the volume of information that is obtained regarding the prostate in general, including the ability to perform a retrospective staging analysis. These factors justify that MR cannot be out rightly rejected as a screening tool based on costs alone. Furthermore, it can also reduce the tendency to take a large number of cores (12 -18) as is currently followed by some centres. Our study shows that even with a randomly done sextant biopsy, detection rates are reasonably high. This study had a few limitations. Firstly, it lacked a whole mount prostate as the histopathologic reference standard. The mpMRI findings were correlated only with the results of TRUS-guided prostate biopsy cores. A suspected malignant focus in prostate on mpMRI might not be accurately targeted at TRUS-guided prostate biopsy. Secondly, random prostatic biopsy might have missed a few small malignant foci. Despite these limitations, the results show that MR can often predict the presence or absence of disease at clinically acceptable level. Further studies in this direction can cement the role of mp-MRI as a screening tool detection of prostate cancer.
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